14-Oct-2026
No press releases found.
Healthcare, biotech, pharma are key diversifiers as AI disrupts digital economy – UBS
Seeking Alpha News (Mon, 12-Oct 1:00 PM ET)
The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index. The Solactive Genomics Index tracks the price movements in shares of companies which are active in the field of Genomics. These companies include those involved in the following business activities: gene editing, genomic sequencing, development and testing of genetic medicine or therapies, computational genomics and genetic diagnostics or biotechnology.
Global X Genomics & Biotechnology ETF trades on the NASDAQ stock market under the symbol GNOM.
As of October 14, 2026, GNOM stock price climbed to $65.91 with 25,083 million shares trading.
GNOM has a beta of 1.00, meaning it tends to be less sensitive to market movements. GNOM has a correlation of 0.17 to the broad based SPY ETF.
GNOM has a market cap of $103.79 million. This is considered a Micro Cap stock.
In the last 3 years, GNOM traded as high as $74.19 and as low as $27.20.
GNOM has outperformed the market in the last year with a return of +62.3%, while the SPY ETF gained +17.4%. In the last 3 month period, GNOM beat the market returning +18.5%, while SPY returned +2.6%. However, in the most recent 2 weeks GNOM has underperformed the stock market by returning -6.3%, while SPY returned +0.9%.
GNOM support price is $63.76 and resistance is $66.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNOM shares will trade within this expected range on the day.
